• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血浆可溶性生物标志物可反映进行性骨化性纤维发育不良(FOP)的急性和慢性炎症状态。

Plasma-Soluble Biomarkers for Fibrodysplasia Ossificans Progressiva (FOP) Reflect Acute and Chronic Inflammatory States.

机构信息

Departments of Medicine and Physiology/Biomedical Engineering, Mayo Clinic Alix School of Medicine, Mayo Clinic, Rochester, MN, USA.

Department of Orthopaedic Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.

出版信息

J Bone Miner Res. 2022 Mar;37(3):475-483. doi: 10.1002/jbmr.4492. Epub 2022 Jan 24.

DOI:10.1002/jbmr.4492
PMID:34954853
Abstract

Fibrodysplasia ossificans progressiva (FOP) is a progressive, debilitating genetic disease in which skeletal muscle and connective tissue is episodically replaced by heterotopic bone. Discovery of surrogate biomarkers of disease (genotype)-related and flare-up-associated activity of FOP in a readily accessible matrix, such as plasma, would facilitate an understanding of the complex pathophysiology of FOP, aid patient care, and provide a valuable tool for the development and monitoring of potential therapeutics. In a case-control study, using a carefully collected and curated set of plasma samples from 40 FOP patients with the classic ACVR1 mutation and 40 age- and sex-matched controls, we report the identification of disease-related and flare-up-associated biomarkers of FOP using a multiplex analysis of 113 plasma-soluble analytes. Adiponectin (implicated in hypoxia, inflammation, and heterotopic ossification) as well as tenascin-C (an endogenous activator of innate immune signaling through the TLR4 pathway and a substrate for kallikrein-7) were highly correlated with FOP genotype, while kallikrein-7 was highly correlated with acute flare-up status. Plasma-soluble biomarkers for FOP support a flare-up-related acute inflammatory phase of disease activity superimposed on a genotypic background of chronic inflammation. © 2021 American Society for Bone and Mineral Research (ASBMR).

摘要

进行性骨化性纤维发育不良(FOP)是一种进行性、使人虚弱的遗传性疾病,其特征是骨骼肌和结缔组织间歇性地被异位骨取代。在易于获得的基质(如血浆)中发现与疾病(基因型)相关的替代生物标志物和 FOP 发作相关的活性,将有助于理解 FOP 的复杂病理生理学,辅助患者护理,并为潜在治疗药物的开发和监测提供有价值的工具。在一项病例对照研究中,我们使用精心收集和精心整理的 40 名携带经典 ACVR1 突变的 FOP 患者和 40 名年龄和性别匹配的对照者的血浆样本,使用对 113 种血浆可溶性分析物的多重分析,报告了 FOP 的与疾病相关和发作相关的生物标志物的鉴定。脂联素(与缺氧、炎症和异位骨化有关)以及 tenascin-C(通过 TLR4 途径激活固有免疫信号的内源性激活剂,也是激肽释放酶-7 的底物)与 FOP 基因型高度相关,而激肽释放酶-7 与急性发作状态高度相关。FOP 的血浆可溶性生物标志物支持疾病活动的发作相关急性炎症相叠加在慢性炎症的基因型背景上。 © 2021 美国骨矿研究学会(ASBMR)。

相似文献

1
Plasma-Soluble Biomarkers for Fibrodysplasia Ossificans Progressiva (FOP) Reflect Acute and Chronic Inflammatory States.血浆可溶性生物标志物可反映进行性骨化性纤维发育不良(FOP)的急性和慢性炎症状态。
J Bone Miner Res. 2022 Mar;37(3):475-483. doi: 10.1002/jbmr.4492. Epub 2022 Jan 24.
2
Overexpression of Wild-Type ACVR1 in Fibrodysplasia Ossificans Progressiva Mice Rescues Perinatal Lethality and Inhibits Heterotopic Ossification.野生型 ACVR1 在进行性骨化性纤维发育不良小鼠中的过表达可挽救围产期致死性并抑制异位骨化。
J Bone Miner Res. 2022 Nov;37(11):2077-2093. doi: 10.1002/jbmr.4617. Epub 2022 Jul 3.
3
The ACVR1 R206H mutation found in fibrodysplasia ossificans progressiva increases human induced pluripotent stem cell-derived endothelial cell formation and collagen production through BMP-mediated SMAD1/5/8 signaling.在进行性骨化性纤维发育不良中发现的ACVR1 R206H突变通过BMP介导的SMAD1/5/8信号通路增加人诱导多能干细胞衍生的内皮细胞形成和胶原蛋白生成。
Stem Cell Res Ther. 2016 Aug 17;7(1):115. doi: 10.1186/s13287-016-0372-6.
4
Depletion of Mast Cells and Macrophages Impairs Heterotopic Ossification in an Acvr1 Mouse Model of Fibrodysplasia Ossificans Progressiva.破骨细胞和巨噬细胞耗竭可损害 Acvr1 小鼠纤维性骨发育不良进展性异位骨化模型中的异位骨化。
J Bone Miner Res. 2018 Feb;33(2):269-282. doi: 10.1002/jbmr.3304. Epub 2018 Jan 3.
5
Matrix metalloproteinase-9 deficiency confers resilience in fibrodysplasia ossificans progressiva in a man and mice.基质金属蛋白酶-9缺乏赋予一名男性和小鼠对进行性骨化性纤维发育不良的抵抗力。
J Bone Miner Res. 2024 May 2;39(4):382-398. doi: 10.1093/jbmr/zjae029.
6
Acute and chronic rapamycin use in patients with Fibrodysplasia Ossificans Progressiva: A report of two cases.成骨不全性骨形成不全进展期患者中急性和慢性雷帕霉素的应用:两例报告。
Bone. 2018 Apr;109:281-284. doi: 10.1016/j.bone.2017.12.011. Epub 2017 Dec 11.
7
Functional Testing of Bone Morphogenetic Protein (BMP) Pathway Variants Identified on Whole-Exome Sequencing in a Patient with Delayed-Onset Fibrodysplasia Ossificans Progressiva (FOP) Using ACVR1 -Specific Human Cellular and Zebrafish Models.全外显子测序鉴定的骨形态发生蛋白(BMP)通路变异在迟发性进行性骨化性纤维发育不良(FOP)患者中的功能检测:使用 ACVR1 特异性人细胞和斑马鱼模型。
J Bone Miner Res. 2022 Nov;37(11):2058-2076. doi: 10.1002/jbmr.4711. Epub 2022 Nov 15.
8
Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1.典型和非典型进行性骨化性纤维发育不良(FOP)表型是由骨形态发生蛋白(BMP)I型受体ACVR1中的突变引起的。
Hum Mutat. 2009 Mar;30(3):379-90. doi: 10.1002/humu.20868.
9
The serum levels of activin A and bone morphogenetic protein-4 and -6 in patients with fibrodysplasia ossificans progressiva.成骨不全性骨纤维发育不良患者血清激活素 A 和骨形态发生蛋白-4 和 -6 水平。
Orphanet J Rare Dis. 2023 May 10;18(1):111. doi: 10.1186/s13023-023-02708-3.
10
Reduced GS Domain Serine/Threonine Requirements of Fibrodysplasia Ossificans Progressiva Mutant Type I BMP Receptor ACVR1 in the Zebrafish.成纤维细胞生长因子受体 1 型突变型骨化性纤维发育不良 BMP 受体在斑马鱼中 GS 结构域丝氨酸/苏氨酸需求减少。
J Bone Miner Res. 2023 Sep;38(9):1364-1385. doi: 10.1002/jbmr.4869. Epub 2023 Jul 17.

引用本文的文献

1
Advancements in mechanisms and drug treatments for fibrodysplasia ossificans progressiva.进行性骨化性纤维发育不良的发病机制及药物治疗进展
J Zhejiang Univ Sci B. 2025 Apr 23;26(4):317-332. doi: 10.1631/jzus.B2300779.
2
[F]NaF PET/CT as a Marker for Fibrodysplasia Ossificans Progressiva: From Molecular Mechanisms to Clinical Applications in Bone Disorders.氟[18F]去铁胺 PET/CT 作为成骨不全性骨纤维发育异常的标志物:从分子机制到骨骼疾病的临床应用。
Biomolecules. 2024 Oct 10;14(10):1276. doi: 10.3390/biom14101276.
3
Performance of simplified methods for quantification of [F]NaF uptake in fibrodysplasia ossificans progressiva.
进行性骨化性纤维发育不良中[F]氟化钠摄取定量简化方法的性能
Front Nucl Med. 2024 Jul 22;4:1406947. doi: 10.3389/fnume.2024.1406947. eCollection 2024.
4
Cell Senescence in Heterotopic Ossification.异位骨化中的细胞衰老
Biomolecules. 2024 Apr 16;14(4):485. doi: 10.3390/biom14040485.
5
Immunologic Aspects in Fibrodysplasia Ossificans Progressiva.进行性骨化性纤维发育不良的免疫学方面。
Biomolecules. 2024 Mar 16;14(3):357. doi: 10.3390/biom14030357.
6
Matrix metalloproteinase-9 deficiency confers resilience in fibrodysplasia ossificans progressiva in a man and mice.基质金属蛋白酶-9缺乏赋予一名男性和小鼠对进行性骨化性纤维发育不良的抵抗力。
J Bone Miner Res. 2024 May 2;39(4):382-398. doi: 10.1093/jbmr/zjae029.
7
TGF-Beta Induces Activin A Production in Dermal Fibroblasts Derived from Patients with Fibrodysplasia Ossificans Progressiva.TGF-β诱导进行性骨化性纤维发育不良患者来源的真皮成纤维细胞产生激活素 A。
Int J Mol Sci. 2023 Jan 24;24(3):2299. doi: 10.3390/ijms24032299.
8
Diminished muscle integrity in patients with fibrodysplasia ossificans progressiva assessed with at-home electrical impedance myography.应用家庭式电阻抗肌图评估进行性骨化性纤维发育不良患者的肌肉完整性受损。
Sci Rep. 2022 Dec 3;12(1):20908. doi: 10.1038/s41598-022-25610-7.
9
Suppression of heterotopic ossification in fibrodysplasia ossificans progressiva using AAV gene delivery.使用 AAV 基因传递抑制纤维发育不良性骨化进展中的异位骨化。
Nat Commun. 2022 Oct 19;13(1):6175. doi: 10.1038/s41467-022-33956-9.